Imdex First Half 2025 Earnings: EPS: AU$0.061 (vs AU$0.033 in 1H 2024)
Revenue: AU$212.0m (down 9.9% from 1H 2024).
Net income: AU$31.0m (up 84% from 1H 2024).
Profit margin: 15% (up from 7.1% in 1H 2024). The increase in margin was driven by lower expenses.
EPS: AU$0.061 (up from AU$0.033 in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Metals and Mining industry in Australia.
Performance of the Australian Metals and Mining industry.
The company's shares are up 10% from a week ago.
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Imdex's balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BESIX Watpac constructs distribution centre for Woolworths in Sydney
BESIX Watpac, the Australian multidisciplinary construction subsidiary of BESIX Group, is currently designing and constructing the Woolworths Sydney Chilled and Fresh Distribution Center in Eastern Creek, Australia. The facility is forecast to become the largest multistorey, temperature-controlled distribution centre in the Southern Hemisphere. Spanning over 93,000m², it will feature chilled and fresh warehousing across two floors, ancillary buildings, office space, and a four-storey above-ground car park with 762 spaces, alongside heavy vehicle parking. Additionally, 23,607m² of solar panels will be installed to partially power the facility. BESIX Watpac CEO Mark Baker said: 'We are looking forward to delivering this cutting-edge facility for Woolworths Group. It's great to see our experienced team bring its expertise here, many of whom are Western Sydney locals. "Procuring a lot of our trades through the local workforce and subcontractors makes it even more exciting for our organisation, particularly on a project of this size and scale." Upon starting operations, the site is expected to manage over 6,000 tonnes (t) of fruit, vegetables, and chilled products daily. This will play a crucial role in supplying fresh products to customers in Sydney, Canberra, and regional New South Wales, as well as extending the shelf life of fresh produce to minimise food waste by utilising advanced refrigeration technology. The construction phase of the project is generating more than 4,000 local jobs and fostering partnerships with numerous local businesses. Upon completion, the facility is projected to employ up to 700 people by 2027. Located at a motorway intersection in Western Sydney, the distribution centre will enhance efficiency for suppliers and transport operators, states BESIX Watpac. Since construction began seven months ago, the project has seen rapid progress, with over 200,000 construction hours recorded and nearly 1,000 local people having worked on the project to date. Recently, BESIX announced the topping out of the POST Rotterdam project in the Netherlands. "BESIX Watpac constructs distribution centre for Woolworths in Sydney" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
3 Growth Companies With High Insider Ownership Achieving 101% Earnings Growth
As the S&P 500 reaches new heights and investor confidence is bolstered by strong economic data, the focus on growth companies with high insider ownership becomes increasingly relevant. In today's market environment, stocks that combine robust earnings growth with significant insider investment can be particularly appealing, as they often signal strong internal confidence and alignment with shareholder interests. Name Insider Ownership Earnings Growth Super Micro Computer (SMCI) 16.2% 39.1% Ryan Specialty Holdings (RYAN) 15.5% 91% Prairie Operating (PROP) 34.2% 71.1% FTC Solar (FTCI) 27.9% 62.5% Enovix (ENVX) 12.1% 58.4% Eagle Financial Services (EFSI) 15.8% 82.8% Duolingo (DUOL) 14.3% 40% Credo Technology Group Holding (CRDO) 12.1% 45% Atour Lifestyle Holdings (ATAT) 22.7% 24.1% Astera Labs (ALAB) 15.1% 44.4% Click here to see the full list of 187 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Bridgewater Bancshares, Inc. is a bank holding company for Bridgewater Bank, offering various banking products and services in the United States with a market cap of $397.88 million. Operations: The company generates revenue primarily from its banking segment, amounting to $111.39 million. Insider Ownership: 20.6% Earnings Growth Forecast: 22.8% p.a. Bridgewater Bancshares exhibits strong growth potential with earnings forecasted to grow at 22.8% annually, outpacing the US market's 14.5%. Recent Q1 earnings showed net income rising to US$9.63 million from US$7.83 million year-over-year, indicating robust financial performance. However, insider activity reveals substantial selling over the past three months despite shares trading significantly below fair value estimates. The company also completed a share buyback of 3.29% for US$10.35 million, reflecting strategic capital management decisions. Dive into the specifics of Bridgewater Bancshares here with our thorough growth forecast report. The analysis detailed in our Bridgewater Bancshares valuation report hints at an deflated share price compared to its estimated value. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $362.80 million. Operations: The company's revenue primarily comes from its regenerative medicine segment, which generated $458.76 million. Insider Ownership: 37.6% Earnings Growth Forecast: 101.7% p.a. Organogenesis Holdings is experiencing significant growth potential, with earnings forecasted to grow 101.69% annually and expected profitability within three years. Despite a volatile share price recently, the company trades at good value relative to peers. Recent Q1 results showed a decline in sales to US$86.69 million and an increased net loss of US$18.84 million year-over-year but reaffirmed its revenue guidance for 2025, projecting up to US$535 million in revenue with improved gross margins. Navigate through the intricacies of Organogenesis Holdings with our comprehensive analyst estimates report here. Our expertly prepared valuation report Organogenesis Holdings implies its share price may be lower than expected. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Viant Technology Inc. operates as an advertising technology company with a market cap of $864.67 million. Operations: The company generates revenue of $306.48 million from its Internet Information Providers segment. Insider Ownership: 12.2% Earnings Growth Forecast: 27.4% p.a. Viant Technology's earnings are forecast to grow significantly, outpacing the broader US market. Despite a recent net loss of US$1.19 million in Q1 2025, sales increased to US$70.64 million from the previous year. The company anticipates Q2 revenue between US$77 million and US$80 million. Trading well below its estimated fair value, analysts expect a stock price increase of 58.4%, highlighting potential for substantial growth despite current low return on equity projections. Unlock comprehensive insights into our analysis of Viant Technology stock in this growth report. The valuation report we've compiled suggests that Viant Technology's current price could be quite moderate. Click here to access our complete index of 187 Fast Growing US Companies With High Insider Ownership. Ready To Venture Into Other Investment Styles? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include BWB ORGO and DSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month
TG Therapeutics saw its share price rise by 13% last month. This period witnessed significant market fluctuations, such as the S&P 500 hitting 6,000 for the first time since February and strong job reports boosting economic sentiment. These positive macroeconomic developments likely provided a supportive backdrop for TG Therapeutics' stock performance. While specific corporate events for TG Therapeutics were not highlighted, broader economic trends, including subsiding tariff concerns and robust corporate earnings, may have indirectly influenced its upward price movement, complementing the overall positive sentiment in the equity markets. Be aware that TG Therapeutics is showing 1 warning sign in our investment analysis. This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. The recent surge in TG Therapeutics's share price, amid broader market positivity, aligns well with the company's growth narrative driven by the international expansion of BRIUMVI and ongoing trials. The positive economic environment has likely supported the stock's upward momentum, which could, in turn, positively impact revenue and earnings forecasts by enhancing investor sentiment and facilitating access to capital. Despite this short-term boost, it's important to consider that the long-term growth trajectory will depend heavily on successful execution of international expansion strategies and the outcome of ongoing clinical trials. Over the past three years, TG Therapeutics's impressive total return, including dividends, reached a very large percentage, providing substantial context for the current market enthusiasm. Notably, the company outperformed the US Market, which saw an 11% return over the last year, as well as the US Biotechs industry, which returned -12.1%, marking TG Therapeutics as a standout performer on both fronts. Compared to these benchmarks, the company's longer-term performance adds significant weight to its growth narrative. The price movement, in light of the analyst consensus price target of US$43.0, shows that TG Therapeutics's current share price is roughly in line with expectations, with only a small deviation indicating that the market sees the company as fairly valued at present. This alignment suggests that analysts' future expectations, particularly regarding revenue and earnings growth, are already factored into the current share price, underscoring the importance of delivering on those growth forecasts to maintain investor confidence. Dive into the specifics of TG Therapeutics here with our thorough balance sheet health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:TGTX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
